Celebrating our researcher at Women in STEM Awards
6th June 2022
Congratulations to Dr Elena De Vita, based at Imperial College London, who was highly commended in the Life Sciences category at the L’Oréal-UNESCO For Women In Science awards. The awards celebrate exceptional early career female scientists in the UK and Ireland.
At Worldwide Cancer Research, we believe we have a responsibility to all cancer patients, present and future, to search for the most innovative ideas from researchers around the world so that we can start new cancer cures. You can read more about our commitment to opportunity without barriers in our diversity statement. Increasing diversity in science is incredibly important to us and so we applaud the L’Oreal-UNESCO programme which aims to promote, enhance and encourage the contribution of women pursuing research careers.
Over 200 applicants were received for the programme, however only ten were selected for prizes. The winners and those commended for their work were presented with their awards at the prestigious ceremony, held at the House of Commons in London on 25th May 2022. Dr De Vita received a high commendation for her research into breast cancer, the most common form of cancer.
Dr De Vita and her team within Professor Edward Tate’s research group at Imperial are studying how breast cancer spreads to other organs. She hopes that by blocking a protein involved in messaging cells could prevent this happening and potentially be an effective new treatment for patients.
I am overjoyed to have been selected alongside this pool of incredible scientists. The L’Oréal-UNESCO programme is a “one-of-a-kind” platform to promote the work of women in STEM and this nomination will significantly accelerate my research towards next-generation cancer therapeutics.
The L’Oréal-UNESCO programme is an important celebration of the fantastic work carried out by female scientists. We are proud Dr De Vita has been recognised for her innovative research on breast cancer which we hope will lead to new treatments in the future.